Hansa Biopharma Toekomstige groei

Future criteriumcontroles 2/6

Hansa Biopharma zal naar verwachting groeien in winst en omzet met respectievelijk 43.2% en 47.9% per jaar. De winst per aandeel zal naar verwachting groeien met 48.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -84.7% zijn.

Belangrijke informatie

43.2%

Groei van de winst

48.3%

Groei van de winst per aandeel

Biotechs winstgroei	48.4%
Inkomstengroei	47.9%
Toekomstig rendement op eigen vermogen	-84.7%
Dekking van analisten	Low
Laatst bijgewerkt	20 Oct 2024

Recente toekomstige groei-updates

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Oct 20

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21

Recent updates

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Oct 20

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Aug 24

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

May 21

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01

Winst- en omzetgroeiprognoses

OM:HNSA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	537	-508	-231	-211	3
12/31/2025	367	-546	-354	-339	4
12/31/2024	243	-632	-505	-498	4
9/30/2024	189	-655	-700	-700	N/A
6/30/2024	164	-802	-744	-744	N/A
3/31/2024	166	-845	-738	-738	N/A
12/31/2023	134	-832	-756	-756	N/A
9/30/2023	114	-856	-697	-693	N/A
6/30/2023	159	-759	-630	-626	N/A
3/31/2023	148	-678	-583	-579	N/A
12/31/2022	155	-611	-506	-503	N/A
9/30/2022	139	-626	-509	-509	N/A
6/30/2022	77	-620	-514	-514	N/A
3/31/2022	55	-583	-493	-491	N/A
12/31/2021	34	-548	-484	-481	N/A
9/30/2021	22	-491	-464	-461	N/A
6/30/2021	18	-465	-327	-325	N/A
3/31/2021	14	-431	-291	-290	N/A
12/31/2020	6	-421	-291	-290	N/A
9/30/2020	3	-426	-270	-269	N/A
6/30/2020	3	-398	-357	-354	N/A
3/31/2020	3	-381	-358	-354	N/A
12/31/2019	3	-360	-338	-335	N/A
9/30/2019	4	-330	-320	-317	N/A
6/30/2019	3	-298	-293	-291	N/A
3/31/2019	4	-274	-264	-262	N/A
12/31/2018	3	-248	-207	-205	N/A
9/30/2018	3	-216	-179	-176	N/A
6/30/2018	3	-192	N/A	-161	N/A
3/31/2018	3	-178	N/A	-150	N/A
12/31/2017	3	-177	N/A	-150	N/A
9/30/2017	3	-161	N/A	-148	N/A
6/30/2017	3	-151	N/A	-137	N/A
3/31/2017	3	-136	N/A	-121	N/A
12/31/2016	3	-111	N/A	-95	N/A
9/30/2016	4	-97	N/A	-83	N/A
6/30/2016	3	-84	N/A	-72	N/A
3/31/2016	3	-76	N/A	-67	N/A
12/31/2015	7	-66	N/A	-58	N/A
9/30/2015	5	-60	N/A	-50	N/A
6/30/2015	5	-51	N/A	-39	N/A
3/31/2015	4	-34	N/A	-29	N/A
12/31/2014	2	-29	N/A	-24	N/A
9/30/2014	2	-21	N/A	-19	N/A
6/30/2014	3	-20	N/A	-17	N/A
3/31/2014	3	-19	N/A	-14	N/A
12/31/2013	2	-18	N/A	-15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat HNSA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat HNSA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat HNSA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van HNSA ( 47.9% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.03% per jaar).

Hoge groei-inkomsten: De omzet van HNSA ( 47.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat HNSA binnen 3 jaar verliesgevend zal zijn.

Hansa Biopharma Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Consensus revenue estimates fall by 18%

Price target decreased by 7.0% to kr103

Consensus revenue estimates increase by 17%

Consensus revenue estimates decrease by 21%

Recent updates

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings released: kr4.15 loss per share (vs kr3.92 loss in 1Q 2023)

Consensus revenue estimates fall by 18%

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

New minor risk - Share price stability

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

Price target decreased by 7.0% to kr103

Consensus revenue estimates increase by 17%

New minor risk - Shareholder dilution

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Hansa Biopharma AB (Publ) Announces CFO Changes

Consensus revenue estimates decrease by 16%, EPS upgraded

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Financial position

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

President & CEO recently bought kr115k worth of stock

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Profitability

Consensus revenue estimates fall by 17%

Price target decreased by 12% to kr148

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

New minor risk - Share price stability

Consensus revenue estimates decrease by 33%

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Consensus EPS estimates fall by 11%, revenue upgraded

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 10%, revenue upgraded

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic